(Q30577903)

English

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

based on heuristic

inferred from title

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Matthew J Armstrong

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Jeremy W Tomlinson

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

D D Houlihan

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

I A Rowe

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

W H O Clausen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

B Elbrønd

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

S C L Gough

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

0 references

publication date

19 November 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

37

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

234-242

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Endpoints and clinical trial design for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Updated definitions of healthy ranges for serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Identifiers

10.1111/APT.12149

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30577903&oldid=1548534720"